Pacira BioSciences (PCRX) Change in Acquisitions & Divestments (2011 - 2026)

Pacira BioSciences' Change in Acquisitions & Divestments history runs 16 years deep, the most recent figure standing at $22.5 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments fell 67.51% year-over-year to $22.5 million in Q1 2026; TTM through Mar 2026 was $227.1 million, a 10.51% increase from a year earlier, with the FY2025 full-year figure at $273.8 million, up 52.48% from the prior year.
• Change in Acquisitions & Divestments declined to $22.5 million in Q1 2026 per PCRX's latest filing, from $47.1 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $126.2 million in Q1 2023 and bottomed at $22.5 million in Q1 2026.
• The 5-year median for Change in Acquisitions & Divestments is $50.2 million (2024), against an average of $59.4 million.
• Biggest YoY gain for Change in Acquisitions & Divestments was 146.2% in 2022; the steepest drop was 80.57% in 2022.
• Year by year, Change in Acquisitions & Divestments stood at $84.9 million in 2022, then sank by 57.5% to $36.1 million in 2023, then jumped by 30.05% to $46.9 million in 2024, then gained by 0.42% to $47.1 million in 2025, then plunged by 52.27% to $22.5 million in 2026.
• Per Business Quant, the three latest PCRX Change in Acquisitions & Divestments figures stand at $22.5 million (Q1 2026), $47.1 million (Q4 2025), and $86.2 million (Q3 2025).